🇺🇸 FDA
Patent

US 8143279

Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

granted A61PA61P1/00A61P1/04

Quick answer

US patent 8143279 (Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists) held by Theravance, Inc. expires Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Mar 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61P, A61P1/00, A61P1/04, A61P1/10, A61P1/14